HUMA (Humacyte) Net Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Humacyte Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Humacyte's Net Income for the three months ended in Sep. 2024 was $-39.20 Mil. Humacyte's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Humacyte's net margin for the quarter that ended in Sep. 2024 was 0.00%.

The historical rank and industry rank for Humacyte's Net Margin % or its related term are showing as below:

HUMA's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -133.185
* Ranked among companies with meaningful Net Margin % only.

Humacyte Net Margin % Historical Data

The historical data trend for Humacyte's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Humacyte Net Margin % Chart

Humacyte Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Net Margin %

Humacyte Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Net Margin %	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of Humacyte's Net Margin %

For the Biotechnology subindustry, Humacyte's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Humacyte's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Humacyte's Net Margin % distribution charts can be found below:

* The bar in red indicates where Humacyte's Net Margin % falls into.

Save Embed

;

Save Embed

;

Humacyte Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Humacyte's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-110.776	/	0
	=	%

Humacyte's Net Margin for the quarter that ended in Sep. 2024 is calculated as

Net Margin	=	Net Income (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-39.202	/	0
	=	%

Humacyte (NAS:HUMA) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Humacyte Net Margin % Related Terms

Thank you for viewing the detailed overview of Humacyte's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Humacyte Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humacyte Inc (NAS:HUMA) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2525 East North Carolina Highway 54, Durham, NC, USA, 27713

Website

https://www.humacyte.com

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.

Executives

Michael T. Constantino	director	C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Laura E Niklason	director, 10 percent owner, officer: President, CEO and Director	35 WILSHIRE ROAD, GREENWICH CT 06831
Brady W Dougan	director, 10 percent owner	35 WILSHIRE ROAD, GREENWICH CT 06831
Kathleen Sebelius	director	C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Dale A. Sander	officer: CFO & CCDO	11304 EMPIRE LAKES DRIVE, RALEIGH NC 27617
Heather Ledbetter Prichard	officer: Chief Operating Officer	820 BROWNWICH STREET, WAKE FOREST NC 27587
Max N. Wallace	director	210 WEST TRYON STREET, HILLSBOROUGH NC 27278
Gordon M Binder	director	225 S. LAKE AVE., SUITE 300, PASADENA CA 91101
Ayabudge Llc	10 percent owner	35 WILSHIRE ROAD, GREENWICH CT 06831
William John Scheessele	officer: Chief Commercial Officer	620 WADE AVENUE, UNIT 501, RALEIGH NC 27605
Yang Cao	officer: Chief Regulatory Officer	12 DOGLEG LANE, LAWRENCE NJ 08648
Charles Bruce Green	director	3185 SCENIC DRIVE, NAPA CA 94558
Diane Seimetz	director	JUTASTRASSE, MUNICH 2M 80636
Shamik J Parikh	officer: Chief Medical Officer	1160 HEDGEROW DRIVE, GARNET VALLEY PA 19060
Rajiv Shukla	director	EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411